EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France

Hervé Chambost iD, Yohann Repessé, Fabienne Genre-Volot, Dominique Desprez, Sabine Marie Castet, Stéphane Vanderbecken, Meriem Zidi, Corinne Gandossi, Eveline Nüesch, Helena Palmborg, Elena Santagostino, B-SURE Study Group

Therapeutic Advances in Hematology · 2025-07 · 16

DOI: 10.1177/20406207241311535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 26.01.2025. Verfasst von Hervé Chambost und 11 weiteren Autor:innen. Beteiligte Einrichtung: AP-HM, Department of Paediatric Haematology, Immunology and Oncology, La Timone Children's Hospital and Aix Marseille University, C2VN, Marseille, Fr…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sobi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

More real-world data are needed to complement existing phase III studies on the efficacy and safety of recombinant factor IX Fc fusion protein (rFIXFc) in people with haemophilia B.

Objectives

We report final data from the B-SURE study, evaluating the real-world usage and effectiveness of rFIXFc in France.

Methods

Previously treated patients (all ages/severities) received on-demand or prophylactic rFIXFc during B-SURE. Annualised bleeding rate (ABR), injection frequency (IF) and factor consumption (FC) were prospectively evaluated for patients on rFIXFc prophylaxis (primary endpoints). Six months of retrospective factor IX (FIX) data were collected for comparison; patients with ⩾3 months of treatment pre- and post-switch to rFIXFc were analysed.

Design

B-SURE was a 24-month, prospective, non-interventional, real-world study across haemophilia treatment centres in France.

Results

Ninety-one male patients enrolled across 21 centres (34%

Schlagwörter

Stichwörter der Autor:innen

factor IXhaemophilia Bprophylaxisrecombinant fusion proteins

Autor:innen und Institutionen

  • AP-HM, Department of Paediatric Haematology, Immunology and Oncology, La Timone Children's Hospital and Aix Marseille University, C2VN, Marseille, France.
  • Haemophilia Treatment Centre, University Hospital of Caen, Caen, France.
  • Haemophilia Treatment Centre, University Hospital of Dijon, Dijon, France.
  • Haemophilia Treatment Centre, University Hospital of Strasbourg, Strasbourg, France.
  • Haemophilia Treatment Centre, University Hospital of Bordeaux, Bordeaux, France.
  • Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, France.

ORCID-Profile: Hervé Chambost

Förderung

  • Sobi

Zitieren

APA

Chambost, H., Repessé, Y., Genre-Volot, F., Desprez, D., Castet, S. M., Vanderbecken, S., Zidi, M., Gandossi, C., Nüesch, E., Palmborg, H., Santagostino, E., & B-SURE Study Group (2025). Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France. Therapeutic Advances in Hematology, 16. https://doi.org/10.1177/20406207241311535

Vancouver

Chambost H, Repessé Y, Genre-Volot F, Desprez D, Castet SM, Vanderbecken S, et al. Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France. Therapeutic Advances in Hematology. 2025;16. doi:10.1177/20406207241311535

BibTeX
@article{Chambost2025,
  author = {Chambost, Hervé and Repessé, Yohann and Genre-Volot, Fabienne and Desprez, Dominique and Castet, Sabine Marie and Vanderbecken, Stéphane and Zidi, Meriem and Gandossi, Corinne and Nüesch, Eveline and Palmborg, Helena and Santagostino, Elena and B-SURE Study Group, B-SURE Study Group},
  title = {Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France},
  journal = {Therapeutic Advances in Hematology},
  year = {2025},
  volume = {16},
  doi = {10.1177/20406207241311535}
}
Kostenlos starten →